Depotech(depo) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Depotech(depo)

DEPO 7.300

+1.7%

Aug 14 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Czechsinthemail who wrote (731)	2/17/1998 10:10:00 PM
From: Dr. John M. de Castro	Read Replies (1) of 887

Baird, I share your concern regarding the chemical arachnoiditis. It was a surprise issue at the ODAC meeting. I asked the company about it during their conference call. They simply said that it was way overblown. This was not a real satisfactory answer. I further asked them about it in regard to the Phase IV trial. The only answer I got was that the patients were being better about adhering to their schedule of steroids than in the Phase III. They did not elaborate or indicate whether this was improving the situation. It's a wild card issue. If anyone knows more about how serious this is I'd appreciate hearing about it. John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next